These work by reducing excess melanin production and supporting a healthier glow
In SURMOUNT 4, all participants received the maximum tolerated dose of tirzepatide for 36 weeks and were then randomized 1:1 to continue tirzepatide or receive placebo until 88 weeks
For BPC-157 to move from experimental to evidence-based, the research community would need: Phase I (Safety) 50-100 healthy volunteers Multiple dose levels Comprehensive pharmacokinetic profiling Adverse event monitoring for 4-8 weeks minimum Phase II (Efficacy Signals) 100-300 patients with specific conditions Randomized, placebo-controlled design Validated outcome measures 3-6 month follow-up minimum Phase III (Confirmatory) 500-3000 patients Multi-site trials Long-term safety monitoring Comparison to existing treatments Currently, were stuck before Phase I even completes
AOD-9604's role, if it has one, is likely as an adjunct in experimental protocols or in the emerging area of joint and cartilage support not as a standalone fat-loss agent
Having this new option provides physicians with a tool that will help prevent the life-changing amputation of ones frostbitten fingers or toes, said Norman Stockbridge, director of the Division of Cardiology and Nephrology at the FDAs Center for Drugs and Evaluation Research, in a statement
